The i allele of the angiotensin converting enzyme I/D polymorphism confers protection against coronary artery disease

Coronary Artery Disease

Volumn 21, Issue 3, 2010, Pages 151-156

  Abchee, Antoine ^a   El Sibai, Mirvat ^b   Youhanna, Sonia ^b   Yeretzian, Joumana S ^b   Estephan, Hanine ^b   Makhoul, Nadine J ^b   Puzantian, Houry ^a   Sawaya, Jaber ^a   Nasrallah, Antoine ^a   Rebeiz, Abdallah G ^a   Zreik, Tony G ^a   Azar, Sami T ^a   Zalloua, Pierre A ^b,c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Angiotensin; Angiotensin converting enzyme; Coronary artery disease; Genotype; Polymorphisms

Indexed keywords

BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METHYTETRAHYDROFOLATE REDUCTASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DNA POLYMORPHISM; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HEART CATHETERIZATION; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77951296198     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328335a042     Document Type: Article

References (30)

1. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95:1517-1532.
2. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens A 1987; 9:243-259.
3. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006; 98:1123-1133.
4. Soubrier F, Martin S, Alonso A, Visvikis S, Tiret L, Matsuda F, et al. High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity. Eur J Hum Genet 2002; 10:553-561.
5. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.
6. Seckin D, Ilhan N, Ozbay Y. The relationship between ACE insertion/deletion polymorphism and coronary artery disease with or without myocardial infarction. Clin Biochem 2006; 39:50-54.
7. Istrati VF, Butorov IV, Manea DV, Ikim AA, Barbakar NI, Kalenich OS, et al. The incidence of some angiotensin-1 converting enzyme gene alleles in patients with coronary heart disease. Klin Med (Mosk) 2006; 84:22-24.
8. Van Berlo JH, Pinto YM. Polymorphisms in the RAS and cardiac function. Int J Biochem Cell Biol 2003; 35:932-943.
9. Harrap SB, Davidson HR, Connor JM, Soubrier F, Corvol P, Fraser R, et al. The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 1993; 21:455-460. (Pubitemid 23095158)
10. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000; 20:484-492.
11. Tuncer N, Tuglular S, KiliçG, Sazci A, Us O, Kara I. Evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of ischaemic stroke. J Clin Neurosci 2006; 13:224-227.
12. Kerkeni M, Addad F, Chauffert M, Myara A, Gerhardt M, Chevenne D, et al. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann Clin Biochem 2006; 43:200-206. (Pubitemid 43668152)
13. Botto N, Andreassi MG, Rizza A, Berti S, Bevilacqua S, Federici C, et al. C677 T polymorphism of the methylenetetrahydrofolate reductase gene is a risk factor of adverse events after coronary revascularization. Int J Cardiol 2004; 96:341-345.
14. Falchi A, Giovannoni L, Piras IS, Calo CM, Moral P, Vona G, et al. Prevalence of genetic risk factors for coronary artery disease in Corsica island (France). Exp Mol Pathol 2005; 79:210-213.
15. Gueant-Rodriguez RM, Gué ant JL, Viola M, Tramoy D, Gaeta F, Romano A. Association of MTRRA66G polymorphism (but not of MTHFR C677 T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost 2005; 94:510-515.
16. Rothenbacher D, Fischer HG, Hoffmeister A, Hoffmann MM, März W, Bode G, et al. Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis 2002; 162:193-200.
17. Dawson S, Hamsten A,Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11:183-190.
18. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, et al. Five frequent polymorphisms, of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997; 17:851-858.
19. Smolarz B, Romanowicz-Makowska H, Kulig A. Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer. Acta Biochim Pol 2003; 50:489-495.
20. Mikkelsson J, Perola M,Wartiovaara U, Peltonen L, Palotie A, Penttilä A, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb Haemost 2000; 84:78-82.
21. Canavy I, Henry M, Morange PE, Tiret L, Poirier O, Ebagosti A, et al. Genetic polymorphisms and coronary artery disease in the south of France. Thromb Haemost 2000; 83:212-216.
22. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
23. Ucar F, Celik S, Ovali E, Karti SS, Pakdemir A, Yilmaz M, et al. Coexistence of prothrombic risk factors and its relation to left ventricular thrombus in acute myocardial infarction. Acta Cardiol 2004; 59:33-39.
24. Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol 2006; 47:2141-2151.
25. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM. Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? A systematic review. Curr Control Trials Cardiovasc Med 2005; 6:16.
26. Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol 1999; 34:1778-1783.
27. Tamim H, Finan RR, Almawi WY. Prevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese. Thromb Haemost 2002; 88:691-692.
28. Abchee A, Puzantian H, Azar ST, Shbaklo H, Nasrallah A, Sawaya FJ, et al. Predictors of coronary artery disease in the Lebanese population. Thromb Res 2006; 117:631-637.
29. Beohar N, Damaraju S, Prather A, Yu QT, Raizner A, Kleiman NS, et al. Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Investig Med 1995; 43:275-280.
30. Mathew J, Basheeruddin K, Prabhakar S. Differences in frequency of the deletion polymorphism of the angiotensin-convertingënzyme gene in different ethnic groups. Angiology 2001; 52:375-379.